Regulatory approval

Published by the Health Canada.

Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

This is written in the approval document as:

GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

Citation

Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083190.PDF. Revised January 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HC (1)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib
HC (1)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib
HC (1)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib
HC (1)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib